GSK completes £2bn share buyback programme

GSK plc reports that it has repurchased ordinary shares under its existing buyback programme, using Citigroup Global Markets Limited as broker, and has now completed the buyback of up to £2 billion announced on 24 February 2025.

Rhea-AI Filing Summary

GSK plc reports that it has repurchased ordinary shares under its existing buyback programme, using Citigroup Global Markets Limited as broker, and has now completed the buyback of up to £2 billion announced on 24 February 2025.

Between 22 and 26 June 2026, GSK bought 1,054,653 ordinary shares of 31¼ pence each at volume-weighted average prices between 1,919.89 and 1,967.46 GBp per share. Since 24 February 2025, it has purchased 123,939,156 ordinary shares for aggregate consideration of just under £2 billion. After these purchases, GSK holds 270,881,064 shares in treasury and has 4,045,395,364 ordinary shares in issue, so total voting rights are 4,045,395,364 and 6.70 per cent of voting rights are now attributable to treasury shares.

Insights

Equity capital markets analyst

GSK completes a sizeable £2bn buyback, holding 6.7% of voting rights in treasury shares.

GSK has finished a share repurchase programme of up to £2 billion, buying 123,939,156 ordinary shares since 24 February 2025. The most recent tranche between 22–26 June 2026 totaled 1,054,653 shares at volume-weighted prices around 1,920–1,970 GBp.

Following these transactions, the company holds 270,881,064 shares in treasury and 4,045,395,364 shares remain in issue, with total voting rights of 4,045,395,364. Treasury shares represent 6.70% of voting rights, which can influence per-share metrics depending on future use or cancellation. The activity was executed under a non-discretionary agreement, indicating a pre-defined, programmatic approach.

Key Figures

Recent shares repurchased: 1,054,653 shares VWAP 22 June 2026: 1,919.89 GBp/share VWAP 26 June 2026: 1,964.68 GBp/share +5 more

8 metrics

Recent shares repurchased 1,054,653 shares Total bought between 22–26 June 2026

VWAP 22 June 2026 1,919.89 GBp/share Volume-weighted average price on 216,757 shares

VWAP 26 June 2026 1,964.68 GBp/share Volume-weighted average price on 190,887 shares

Programme size £2 billion Maximum size of completed buyback programme announced 24 Feb 2025

Shares bought in programme 123,939,156 shares Ordinary shares repurchased since 24 February 2025

Treasury shares held 270,881,064 shares Ordinary shares held in treasury after recent purchases

Shares in issue 4,045,395,364 shares Ordinary shares in issue excluding treasury shares

Treasury voting rights 6.70% Percentage of voting rights attributable to treasury shares

Key Terms

Treasury shares, buyback programme, Market Abuse Regulation (EU) No 596/2014, Disclosure Guidance and Transparency Rules, +1 more

5 terms

Treasury shares financial

"The purchased shares will be held as Treasury shares."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

buyback programme financial

"Such share purchases form part of the Company's existing buyback programme"

Market Abuse Regulation (EU) No 596/2014 regulatory

"In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014"

Disclosure Guidance and Transparency Rules regulatory

"under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules."

Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

voting rights financial

"the total number of voting rights in the Company will be 4,045,395,364."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GSK (GSK) announce in its June 2026 Form 6-K?

GSK announced recent purchases of its own ordinary shares and the completion of a share buyback programme of up to £2 billion, originally announced on 24 February 2025, executed through Citigroup Global Markets Limited.

How many GSK shares were repurchased between 22 and 26 June 2026?

GSK repurchased 1,054,653 ordinary shares between 22 and 26 June 2026. Daily purchases ranged from 190,887 to 221,637 shares, with volume-weighted average prices between 1,919.89 GBp and 1,967.46 GBp per share over that period.

What is the total size of GSK’s completed buyback programme?

The completed buyback programme totaled up to £2 billion. Since 24 February 2025, GSK has purchased 123,939,156 ordinary shares for aggregate consideration of just under £2 billion, in line with the amount initially announced for the programme.

How many GSK shares are now held in treasury and in issue?

After the reported purchases, GSK holds 270,881,064 ordinary shares in treasury and has 4,045,395,364 ordinary shares in issue. The shares in issue exclude treasury shares and represent the base for calculating total voting rights in the company.

What are GSK’s total voting rights after the buyback activity?

Total voting rights in GSK are 4,045,395,364 after the buyback activity. Shareholders may use this figure as the denominator when assessing whether they must notify interests under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

What percentage of GSK voting rights do treasury shares now represent?

Treasury shares now represent 6.70 per cent of GSK’s voting rights. This percentage is calculated under DTR 5.5.1R and reflects the voting rights attributable to ordinary shares held in treasury following completion of the reported repurchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 10:25 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through Citigroup Global Markets Limited (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase	Aggregate number of ordinary shares of 31 ¼ pence each purchased	Lowest price paid per share (GBp)	Highest price paid per share (GBp)	Volume weighted average price paid per share (GBp)
22 June 2026	216,757	1,912.00	1,930.50	1,919.89
23 June 2026	221,637	1,915.00	1,971.00	1,948.84
24 June 2026	217,027	1,955.00	1,984.00	1,967.46
25 June 2026	208,345	1,927.00	1,989.50	1,966.85
26 June 2026	190,887	1,945.50	1,995.50	1,964.68

The purchased shares will be held as Treasury shares.

Such share purchases form part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the Company has purchased 9,502,778 ordinary shares.

Following the above purchases, the Company will hold 270,881,064 ordinary shares in treasury and have 4,045,395,364 ordinary shares in issue (excluding Treasury shares).

Following the above purchases, the total number of voting rights in the Company will be 4,045,395,364. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases the percentage of voting rights attributable to the ordinary shares held in treasury is 6.70 per cent.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) is set out in the Schedule to this announcement, available via the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2125K_1-2026-6-29.pdf

These purchases successfully complete the buyback programme of up to £2 billion announced on 24 February 2025. Since 24 February 2025, the Company has purchased 123,939,156 Ordinary Shares, for an aggregate consideration of just under £2 billion, in line with the announced programme.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: June 29, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc